Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yanis Saidi"'
Autor:
Sandrine Bourdoulous, Eric Chevet, Jean-Luc Lenormand, Romy Rothe-Walther, Floriane Carallis, Sandra Bernard, Yanis Saidi, Saïd Taouji, Haniaa Bouzinba-Segard, Anaïs Domingot, Rym Djerbi-Bouillié, Camille Faure
Therapies targeting the tyrosine kinase receptor HER2 have significantly improved survival of patients with HER2+ cancer. However, both de novo and acquired resistance remain a challenge, particularly in the brain metastatic setting. Here we report t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c3694f6c95520f99d2becf4a3a3f837
https://doi.org/10.1158/0008-5472.c.6513291.v1
https://doi.org/10.1158/0008-5472.c.6513291.v1
Autor:
Sandrine Bourdoulous, Eric Chevet, Jean-Luc Lenormand, Romy Rothe-Walther, Floriane Carallis, Sandra Bernard, Yanis Saidi, Saïd Taouji, Haniaa Bouzinba-Segard, Anaïs Domingot, Rym Djerbi-Bouillié, Camille Faure
Supplementary methods and data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f19590e98a90c22ea90d82c145ef856
https://doi.org/10.1158/0008-5472.22429233
https://doi.org/10.1158/0008-5472.22429233
Autor:
Anaïs Domingot, Yanis Saidi, Jean-Luc Lenormand, Saïd Taouji, Haniaa Bouzinba-Segard, Camille Faure, Rym Djerbi-Bouillie, Sandra Bernard, Floriane Carallis, Sandrine Bourdoulous, Romy Rothe-Walther, Eric Chevet
Publikováno v:
Cancer Research
Cancer Research, 2021, ⟨10.1158/0008-5472.CAN-21-0162⟩
Cancer Research, American Association for Cancer Research, 2021, pp.canres.0162.2021. ⟨10.1158/0008-5472.CAN-21-0162⟩
Cancer Research, 2021, 81 (21), pp.5464-5476. ⟨10.1158/0008-5472.CAN-21-0162⟩
Cancer Research, 2021, ⟨10.1158/0008-5472.CAN-21-0162⟩
Cancer Research, American Association for Cancer Research, 2021, pp.canres.0162.2021. ⟨10.1158/0008-5472.CAN-21-0162⟩
Cancer Research, 2021, 81 (21), pp.5464-5476. ⟨10.1158/0008-5472.CAN-21-0162⟩
Therapies targeting the tyrosine kinase receptor HER2 have significantly improved survival of patients with HER2+ cancer. However, both de novo and acquired resistance remain a challenge, particularly in the brain metastatic setting. Here we report t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f0a8996b856bc2c4c0e9d7719dc4b7
https://hal.archives-ouvertes.fr/hal-03369875
https://hal.archives-ouvertes.fr/hal-03369875